Method Validation on Drug Substances

Embed Size (px)

Citation preview

  • 8/2/2019 Method Validation on Drug Substances

    1/41

    Drug Substances

    http://analyticalmethodvalidation.blogspot.com

  • 8/2/2019 Method Validation on Drug Substances

    2/41

    Method Validation

    ObjectiveThe objective of validation of an analyticalprocedure is to demonstrate that it is

    suitable for its intended purpose.

  • 8/2/2019 Method Validation on Drug Substances

    3/41

    Methods to Validate

    IdentificationAssay / DissolutionImpurities

    Quantitative andLimit tests

    Specific Tests

  • 8/2/2019 Method Validation on Drug Substances

    4/41

    ICH Parameters

  • 8/2/2019 Method Validation on Drug Substances

    5/41

    Parameters

    SpecificityPrecisionLinearity and RangeRobustnessAccuracy

    Limit of DetectionLimit of Quantitation

    Assay method

    Related

    Substances

  • 8/2/2019 Method Validation on Drug Substances

    6/41

    Specificity

    Specificity is the ability to assessunequivocally the analyte in the presence ofcomponents which may be expected to bepresent. Typically these might includeimpurities, degradants, matrix, etc.This is applicable for following Porcedures

    IdentificationAssay andImpurities

  • 8/2/2019 Method Validation on Drug Substances

    7/41

    SpecificityFor Assay and Impurities

    Impurities are availableFor Assay

    Spike the pure substances with appropriate levelsof impurities and verify that the assay result is noteffected by the presence of impurities.

    Compare the results of assay with spiked andunspiked samples.

    For example inject matrix containing(spiked)

    Voriconazole and Impurity B(at 0.15%) andidentify the RTs Inject test sample of Voriconazole and identify the

    RT of Voriconazole and Impurity B(at 0.15%). Compare both spiked and test samples

  • 8/2/2019 Method Validation on Drug Substances

    8/41

    Specificity

    For ImpuritiesSpiking the drug substance with appropriatelevels of impurities and demonstrate the

    seperation of these impurities individually orother components from the sample matrix.

    Specificity can be demonstrated by theresolution of the two componenetswhich elute closest to each other.

  • 8/2/2019 Method Validation on Drug Substances

    9/41

    Specificity

    Impurities are not availableDemonstrate the specificity by comparingthe test results of sample containing

    impurities to a second well characterizedprocedure Eg: Pharmacopoiel method orother validated independent procedure.This should include samples stored underrevelent stress conditions

  • 8/2/2019 Method Validation on Drug Substances

    10/41

    Specificity

    Stress testingAcidic/SolutionBasic/Solution

    OxidationThermalThermal / Humidity

    Photo(UV Light)Photo(Fluorecent Light)

  • 8/2/2019 Method Validation on Drug Substances

    11/41

    Specificityfor the assay, the two results should becompared;for the impurity tests, the impurity profiles

    should be compared.Peak purity tests may be useful to showthat the analyte chromatographic peak isnot attributable to more than one

    component (e.g., photodiode array(PDA),mass spectroscopy).Peak purity > 99.9999%Purity angle < purity threshold

  • 8/2/2019 Method Validation on Drug Substances

    12/41

    Specificity

    Acceptance crieteriaPeak purity test must be passed by theactive component and related substances

    There is no interference at the elution zoneof the active component and relatedsubstancesThe resolution between the closest elutedpeaks must be > 2

  • 8/2/2019 Method Validation on Drug Substances

    13/41

    Specificity

    In cases where a non-specific assay isused, other supporting analyticalprocedures should be used to demonstrateoverall specificity.For example, where a titration is adoptedto assay the drug substance for release, the

    combination of the assay and a suitable testfor impurities can be used.

  • 8/2/2019 Method Validation on Drug Substances

    14/41

    Analytical Method Validation Bloghttp://analyticalmethodvalidation.blogspot.com

  • 8/2/2019 Method Validation on Drug Substances

    15/41

    PrecisionThe precision of an analytical procedureexpresses the closeness of agreement(degree of scatter) between a series ofmeasurements obtained from multiplesampling of the same homogeneoussample under the prescribed conditions.Precision may be considered at threelevels:

    repeatability,intermediate precision andreproducibility.

  • 8/2/2019 Method Validation on Drug Substances

    16/41

    Precision

    RepeatabilityA minimum 6 determinations at 100% of thetest concentration.

    Intermediate Precision(ruggedness)The applicant should establish the effects ofrandom events on the precision of theanalytical procedure.Typical variations to be studied include days,analysts, equipment

  • 8/2/2019 Method Validation on Drug Substances

    17/41

    Precision

    ReproducibiliyReproducibility is assessed by means of aninter-laboratory trial..

    These data are not part of the marketingauthorization dossier .The standard deviation, relative standarddeviation (coefficient of variation) andconfidence interval should be reported foreach type of precision investigated.

  • 8/2/2019 Method Validation on Drug Substances

    18/41

    LinearityThe linearity of an analytical procedure is itsability (within a given range) to obtain testresults which are directly proportional to theconcentration (amount) of analyte in thesample.Linearity should be evaluated by visualinspection of a plot of signals as a function ofanalyte concentration or content. If there is a

    linear relationship, test results should beevaluated by appropriate statistical methods,for example, by calculation of a regressionline by the method of least squares

  • 8/2/2019 Method Validation on Drug Substances

    19/41

    Linearity

    The correlation coefficient, y-intercept, slopeof the regression line and residual sum ofsquares should be submitted. A plot of the

    data should be included.For the establishment of linearity, a minimumof 5 concentrations is recommended.

    For Assay method: 80-120%For Related Subsance: from the reporting level ofan impurity 1 to 120% of the specification

  • 8/2/2019 Method Validation on Drug Substances

    20/41

    Detection Limit

    The detection limit of an individual analyticalprocedure is the lowest amount of analyte ina sample which can be detected but not

    necessarily quantitated as an exact value.Several approaches for estabilishing LOD

  • 8/2/2019 Method Validation on Drug Substances

    21/41

    LOD

    Visual InspectionSignal-to-Noise ratioStandard Deviation of the responseand the slope.

    Based on the standard deviation of the blank

    Based on the calibration curve

  • 8/2/2019 Method Validation on Drug Substances

    22/41

    LODBased on Signal-to-NoiseThis approach can only be applied to analyticalprocedures which exhibit baseline noise.Determination of the signal-to-noise ratio isperformed by comparing measured signals fromsamples with known low concentrations of analytewith those of blank samples and establishing theminimum concentration at which the analyte canbe reliably detected.

    A signal-to-noise ratio between 3 or 2:1 isgenerally considered acceptable for estimating thedetection limit.

  • 8/2/2019 Method Validation on Drug Substances

    23/41

    LODBased on the Standard Deviation of theResponse and the SlopeDL =3.3 / S

    = the standard deviation of the responseS = the slope of the calibration curveBased on the Standard Deviation of the Blank

    Measurement of the magnitude of analyticalbackground response is performed by analyzing anappropriate number of blank samples and calculatingthe standard deviation of these responses.

  • 8/2/2019 Method Validation on Drug Substances

    24/41

    LODBased on the Calibration Curve

    A specific calibration curve should be studied usingsamples containing an analyte in the range of DL.The residual standard deviation of a regression line

    or the standard deviation of y-intercepts ofregression lines may be used as the standarddeviation.The detection limit and the method used fordetermining the detection limit should be presented.

    If DL is determined based on visual based on signalto noise ratio, the presentation of the relevantchromatograms is considered acceptable for

    justification.

  • 8/2/2019 Method Validation on Drug Substances

    25/41

    Quantitation Limit

    The quantitation limit of an individual analyticalprocedure is the lowest amount of analyte in asample which can be quantitatively determined

    with suitable precision and accuracy.The quantitation limit is generally determined bythe analysis of samples with knownconcentrations of analyte and by establishingthe minimum level at which the analyte can bequantified with acceptable accuracy andprecision.

  • 8/2/2019 Method Validation on Drug Substances

    26/41

    LOQ

    Visual InspectionSignal-to-Noise ratioStandard Deviation of the responseand the slope.

    Based on the standard deviation of the blank

    Based on the calibration curve

  • 8/2/2019 Method Validation on Drug Substances

    27/41

    LOQBased on Signal-to-Noise ApproachThis approach can only be applied toanalytical procedures that exhibit baselinenoise.Determination of the signal-to-noise ratio isperformed by comparing measured signalsfrom samples with known lowconcentrations of analyte with those of

    blank samples and by establishing theminimum concentration at which theanalyte can be reliably quantified. A typicalsignal-to-noise ratio is 10:1.

  • 8/2/2019 Method Validation on Drug Substances

    28/41

    LOQBased on the Standard Deviation of theResponse and the SlopeThe quantitation limit (QL) may be expressed as:

    QL = 10 /S = the standard deviation of the responseS = the slope of the calibration curve

    The slope S may be estimated from the

    calibration curve of the analyte. The estimate ofmay be carried out in a variety of ways forexample:

  • 8/2/2019 Method Validation on Drug Substances

    29/41

    Accuracy

    The accuracy of an analytical procedureexpresses the closeness of agreementbetween the value which is accepted

    either as a conventional true value or anaccepted reference value and the valuefound.

    This should be performed for both Assayand Related Substances

  • 8/2/2019 Method Validation on Drug Substances

    30/41

    Accuracy

    Accuracy should be assessed on samplespiked with known amounts of impuritiesNine determinations over a minimum 3concentration levels (80, 100 and 120 %)Report the results of recovery as %Recovery

  • 8/2/2019 Method Validation on Drug Substances

    31/41

    Accuracy

    Formula for recovery[(D-A) (C-A)/(B-A)] x 2 for 50%concentration[(D-A) (C-A)/(B-A)] x 2/3 for 150%concentration

    A=Blank

    B=Standard at 100%C=SampleD=Sample+standard(50% or 100% or 150%)

  • 8/2/2019 Method Validation on Drug Substances

    32/41

    Robustness

    The robustness of an analyticalprocedure is a measure of its capacity toremain unaffected by small, but

    deliberate variations in methodparameters and provides an indicationof its reliability during normal usage

    Parameters of robustnessVariabilitySolution stability

  • 8/2/2019 Method Validation on Drug Substances

    33/41

    RobustnessVariabilityVariations in method parameters

    LC PH of a Mobile Phase Mobile Phase Composition Different column Temperature Flow RateGC Different column Temperature Flow rate

  • 8/2/2019 Method Validation on Drug Substances

    34/41

    RobustnessParameter Variability Permitted

    Flow rate 0.1 ml/min

    Mobile Phase Composition 2 % major and Minor component

    Temperature 2C

    Column Different manufacturer

    PH of Mobile Phase 1.0 Units

  • 8/2/2019 Method Validation on Drug Substances

    35/41

    Robustness(example)Parameter Low Actual Higher

    Flow rate 0.4 ml/min 0.5 ml/min 0.6 ml/min

    Temparature 23C 25C 27C

    Column Exp Col-1 Main Column Exp Col-2

    Mobile Phasecomposition

    58:42 60:40 62:38

    pH of mobilephase

    5.0 6.0 7.0

    Mobile Phase Composition50:30:20(A:B:C)Low: ----

  • 8/2/2019 Method Validation on Drug Substances

    36/41

    RobustnessParameter Variability Permitted

    Flow rate 0.1 ml/min

    Mobile Phase Composition 2 % major and Minor component

    Temperature 2C

    Column Different manufacturerPH of Mobile Phase 1.0 Units

  • 8/2/2019 Method Validation on Drug Substances

    37/41

    Robustness(example)Parameter Low Actual Higher

    Flow rate 0.4 ml/min 0.5 ml/min 0.6 ml/min

    Temparature 23C 25C 27C

    Column Exp Col-1 Main Column Exp Col-2

    Mobile Phasecomposition

    58:42 60:40 62:38

    pH of mobilephase

    5.0 6.0 7.0

    Mobile Phase Composition50:30:20(A:B:C)Low: ----

  • 8/2/2019 Method Validation on Drug Substances

    38/41

    Robustness

    Solution stability:Sample, Standard solutions and MobilePhase solutions are prepared during

    chromatographic analysis.Leftover solutions are stored after theanaysis. But we need to verify that thesolution does not loose its properties.

    For the above reason, there is a need toperfrom the stability of analytical solutions atthe time of validation itself.

  • 8/2/2019 Method Validation on Drug Substances

    39/41

    RobustnessSolution stability .

    Standard and sample solutions stored in acapped volumetric flask on a lab bench undernormal lighting conditions for 24 hours to 48hours based on the stability.

    Perform the analysis by injecting same samplesolution at different time intervals. SampleSolution Stability should be monitor up to 24 hrswith minimum 4-5 time intervals or 48 hours withminimum 8-10 intervals. Perform more timeintervals after 12 Hrs. Based on Injection runtime and sequence time establish the samplesolution stability for about 24 Hrs or 48 hours.

  • 8/2/2019 Method Validation on Drug Substances

    40/41

    System Suitability Testing

    System suitability testing is an integralpart of many analytical procedures.Parameters

    Repeatability(RSD)Capacity factor ( k )Relative retention( )

    Resolution(Rs)Tailing factor(T) at W0.05Theoretical plates ( N )

  • 8/2/2019 Method Validation on Drug Substances

    41/41

    Analytical Method Validation Bloghttp://analyticalmethodvalidation.blogspot.com